Abstract
Immunosuppression following pediatric thoracic transplantation is typically centered on the use of calcineurin inhibitors, either cyclosporine or tacrolimus. While there is general agreement on the use of immunosuppressive medications for induction therapy, maintenance immunosuppression, and treatment of acute rejection, there is center-to-center variability with respect to target trough levels, changes in targets over time following transplantation, and selection and use of adjunctive immunosuppressive agents. In this chapter, the medications and therapies used to care for pediatric heart and lung transplant recipients are reviewed and discussed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Calne RY, Rolles K, White DJ et al (1979) Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet 2:1033–1036
Starzl TE, Todo S, Fung JJ et al (1989) FK506 for human liver, kidney, and pancreas transplantation. Lancet 2:1000–1004
Kirk R, Edwards LB, Kucheryavaya AY et al (2011) The registry of the International Society for Heart and Lung Transplantation: fourteenth pediatric heart transplantation report—2011. J Heart Lung Transplant 30:1095–1103
Groetzner J, Meiser B, Landwehr P et al (2004) Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure. Transplantation 77:568–574
Groetzner J, Kaczmarek I, Schulz U et al (2009) Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure. Transplantation 87:726–733
Flechner SM, Kobashigawa J, Klintmalm G (2008) Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transplant 22:1–15
Thomson AW, Bonham CA, Zeevi A (1995) Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit 17:584–591
Kobashigawa JA, Patel J, Furukawa H et al (2006) Five-year results of a randomized, single-center study of tacrolimus vs microemulsion cyclosporine in heart transplant patients. J Heart Lung Transplant 25:434–439
Pirsch JD, Miller J, Deierhoi MH et al (1997) A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 63:977–983
Taketomo CK, Hodding JH, Kraus DM (2011–2012) Pediatric & neonatal dosage handbook, 19th edn. Lexicomp, Hudson, OH
Krämer BK, Charpentier B, Bäckman L et al (2010) Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase III study. Am J Transplant 10:2632–2643
Han DJ, Park JB, Kim YS et al (2012) A 39-month follow-up study to evaluate the safety and efficacy in kidney transplant recipients treated with modified-release tacrolimus (FK506E)-based immunosuppression regimen. Transplant Proc 44:115–117
Robinson BV, Boyle GJ, Miller SA, Law Y, Griffith BP, Webber SA (1999) Optimal dosing of intravenous tacrolimus following pediatric heart transplantation. J Heart Lung Transplant 18:786–791
Pitzalis C, Pipitone N, Bajocchi G et al (1997) Corticosteroids inhibit lymphocyte binding to endothelium and intercellular adhesion: an additional mechanism for their anti-inflammatory and immunosuppressive effect. J Immunol 158:5007–5016
Kasiske BL, Chakkera HA, Louis TA et al (2000) A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 11:1910–1917
Vincenti F, Schena FP, Paraskevas S et al (2008) A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant 8:307–316
Lindenfeld J, Miller GG, Shakar SF et al (2004) Drug therapy in the heart transplant recipient. Part I: cardiac rejection and immunosuppressive drugs. Circulation 110:3734–3740
Munoz R, Schmitt C, Roth S et al (2008) Handbook of pediatric cardiovascular drugs. Springer-Verlag, London
Halloran PF (2004) Immunosuppressive drugs for kidney transplantation. N Engl J Med 351:2715–2729
Merrill JP, Murray JE, Harrison JH et al (1960) Successful homotransplantations of the kidney between non-identical twins. N Engl J Med 262:1251–1260
Starzl TE, Marchioro TL, Waddell WR (1963) The reversal of rejection in human renal homografts with subsequent development of homograft tolerance. Surg Gynecol Obstet 117:385–395
Meier-Kriesche HU, Steffen BJ, Hochberg AM et al (2003) Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection. Am J Transplant 3:68–73
Gourishankar S, Hunsicker LG, Jhangri GS et al (2003) The stability of the glomerular filtration rate after renal transplantation is improving. J Am Soc Nephrol 14:2387–2394
Kobashigawa J, Miller L, Renlund D et al (1998) A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation 66:507–515
Shihab FS, Bennett WM, Yi H et al (2004) Sirolimus increases transforming growth factor-beta1 expression and potentiates chronic cyclosporine nephrotoxicity. Kidney Int 65:1262–1271
Kuppahally S, Al-Khaldi A, Weisshaar D et al (2006) Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients. Am J Transplant 6:986–992
Eisen HJ, Tuzcu EM, Dorent R et al (2003) Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 349:847–858
Meiser BM, Billingham ME, Morris RE (1991) Effects of cyclosporine, FK506, and rapamycin on graft-vessel disease. Lancet 338:1297–1298
Lobach N, Pollock-BarZiv S, West L et al (2005) Sirolimus immunosuppression in pediatric heart transplant recipients: a single-center experience. J Heart Lung Transplant 24:184–189
Behnke-Hall K, Bauer J, Akintuerk H et al (2011) Renal function in children with heart transplantation after switching to CNI-free immunosuppression with everolimus. Pediatr Transplant 15:784–789
Nashan B (2005) Antibody induction therapy in renal transplant patients receiving calcineurin-inhibitor immunosuppressive regimens: a comparative review. BioDrugs 19:39–46
Lundquist AL, Chari RS, Wood JH et al (2007) Serum sickness following rabbit antithymocyte-globulin induction in a liver transplant recipient: case report and literature review. Liver Transpl 13:647–650
Woodside KJ, Lick SD (2007) Alemtuzumab (Campath 1H) as successful salvage therapy for recurrent steroid-resistant heart transplant rejection. J Heart Lung Transplant 26:750–752
Das B, Shoemaker L, Recto M et al (2008) Alemtuzumab (Campath-1H) induction in a pediatric heart transplant: successful outcome and rationale for its use. J Heart Lung Transplant 27:242–244
McCurry KR, Iacono A, Zeevi A et al (2005) Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy. J Thorac Cardiovasc Surg 130:528–537
Campath® (ALEMTUZUMAB) [package insert]. Millennium and ILEX Partners, LP, Cambridge, MA
Morris PJ, Russel NK (2006) Alemtuzumab (Campath-1H): a systematic review in organ transplantation. Transplantation 81:1361–1367
Vincenti F, Larsen C, Durrbach A et al (2005) Costimulation blockade with belatacept in renal transplantation. N Engl J Med 353:770–781
Vincenti F, Dritselis A, Kirkpatrick P (2011) Belatacept. Nat Rev Drug Discov 10:655–656
Vincenti F, Charpentier B, Vanrenterghem Y et al (2010) A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 10:535–546
Korom S (2009) Immunosuppression in cardiac transplantation: state of the art and new drugs. Kardiovaskuläre Medizin 12:272–276
Mehra MR, Zucker MJ, Wagoner L et al (2005) A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation. J Heart Lung Transplant 24:1297–1304
Mattei MF, Redonnet M, Gandjbakhch I et al (2007) Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus anti-thymocyte globulin as induction therapy. J Heart Lung Transplant 26:693–699
Chou NK, Wang SS, Chen YS et al (2008) Induction immunosuppression with basiliximab in heart transplantation. Transplant Proc 40:2623–2625
Kobashigawa J, Crespo-Leiro MG, Ensminger SM et al (2010) Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 30:252–269
Tambur A, Pamboukian SV, Costanzo M et al (2005) The presence of HLA-directed antibodies after heart transplantation is associated with poor allograft outcome. Transplantation 80:1019–1025
Colvin RB, Smith RN (2005) Antibody-mediated organ-allograft rejection. Nat Rev Immunol 5:807–817
Jordan S, Cunningham-Rundles C, McEwan R (2003) Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications. Am J Transplant 3:653–664
Samuelsson A, Towers TL, Ravetch JV (2001) Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291:484–486
Toyoda M, Pao A, Petrosian A et al (2003) Pooled human gammaglobulin modulates surface molecule expression and induces apoptosis in human B cells. Am J Transplant 3:156–166
FDA. US Food and Drug Administration (2012) FDS labeling information – Velcade. FDA website [online], http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021602s027lbl.pdf
Morrow WR, Frazier EA, Mahle WT et al (2012) Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients. Transplantation 93:319–324
Patel J, Everly M, Chang D et al (2011) Reduction of alloantibodies via proteosome inhibition in cardiac transplantation. J Heart Lung Transplant 30:1320–1326
Locke E, Magra CM, Singer DL et al (2009) The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 9:231–35
Dawson KL, Parulekar A, Seethamraju H (2012) Treatment of hyperacute antibody-mediated lung allograft rejection with eculizumab. J Heart Lung Transplant 31:1325–6
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag London
About this entry
Cite this entry
Berry, D., Feingold, B. (2014). Immunosuppressive Medications. In: Da Cruz, E., Ivy, D., Jaggers, J. (eds) Pediatric and Congenital Cardiology, Cardiac Surgery and Intensive Care. Springer, London. https://doi.org/10.1007/978-1-4471-4619-3_133
Download citation
DOI: https://doi.org/10.1007/978-1-4471-4619-3_133
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-4471-4618-6
Online ISBN: 978-1-4471-4619-3
eBook Packages: MedicineReference Module Medicine